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Atorvastatin (ATO) belongs to the statin family of drugs and is widely used for reducing 
cholesterol levels in cardiovascular disease patients.  The target of statin drug therapy is the 3-
hydroxymethyl-3-glutaryl Coenzyme A reductase (HMGCR) - a key rate-limiting regulatory 
enzyme in the mevalonate pathway for cholesterol synthesis. The end products of the 
mevalonate pathway are required for essential cellular functions, including membrane integrity, 
protein synthesis as well as cell proliferation and transformation. Recent evidence shows ATO 
to have a range of pleiotropic effects that includes anti-cancer properties. The antiproliferative 
effects of ATO was investigated on A549 lung carcinoma cells. Cell viability and ATP levels 
were measured by the 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5 diphenyl-2H-tetrazolium bromide 
(MTT), LDH and ATP CellTitre-Glo™ assays, respectively.  Cellular oxidative status was 
evaluated using the Thiobarbituric acid reactive substance (TBARS) and Glutathione (GSH) 
assays. Caspases-3/-7, -8 and −9 activities (luminometry) were determined and DNA integrity 
was assessed via comet and Hoechst 33342 staining assays. Quantitative polymerase chain 
reaction (qPCR) measured cellular mRNA levels of DNA repair enzyme, OGG1. The 
expression of proteins, namely, p53, bax, Bcl-2, Smac/DIABLO, cleaved-PARP and Nrf2 were 
evaluated by western blotting. ATO caused a dose-dependent decrease in cell viability (IC50 of 
39.25µg/ml), a significant increase in extracellular LDH levels (p=0.0051) and significantly 
decreased cellular ATP levels (p=0.0003) whilst significantly increasing lipid peroxidation 
(p=0.0051) and decreasing GSH levels (p=0.0010). DNA integrity was compromised as 
measured by increased DNA fragmentation (p<0.0001) and significantly reduced OGG1 mRNA 
expression (p=0.0363).  Also PARP-1 cleavage was increased (24kDA fragment; p=0.0399). 
ATO induced apoptosis by significantly increasing caspase -8 (p=0.001), −9 (p=0.0143), and -
3/-7 (p=0.0187) activities. Further, ATO increased expression of pro-apoptotic proteins Bax, 
p53 and Smac/DIABLO (p=0.0333; 0.0070; 0.0095) with a concomitant decrease in Bcl-2 and 
Nrf2 expression (p=0.03039; 0.0102). In conclusion, the data shows that ATO is a potent 
inducer of apoptosis (via both the intrinsic and extrinsic apoptotic pathways) in the A549 lung 







Lung cancer is the most common malignancy worldwide, with a high mortality rate, with 
approximately 1.61 million new cases diagnosed each year (Molina, 2008, Mukansi, 2014). The 
incidence of mortality in South Africa (SA) is estimated at 17% of all cancer-related deaths 
(Pacella-Norman, 2002). 
Urbanization and lifestyle changes have seen an increase in the incidence of diseases such as 
lung cancer and cardiovascular disease. Tobacco smoking has been shown to increase both lung 
cancer and cardiovascular disease two-fold compared to non-smokers. The effect of the smoke 
directly inhaled predispose smokers to lung cancer, while absorption of toxic constituents or 
metabolites of smoke contribute to cardiovascular disease (Stein, 2008, Higgenbottam, 1982).  
Conventional cancer treatment regimens such as chemotherapy are expensive and can produce 
acute and chronic organ damage. Thus, it has become necessary to identify improved strategies 
for cancer treatment and prevention (Siegel, 2012). In recent years, the development of 
molecular targeted therapeutics have evolved over common cytotoxic drugs. Many targeted 
agents that modulate specific oncogenic proteins have been approved or that are still under 
development with the hope to achieve better anticancer activity with fewer side effects. 
However, the ability of the tumour to counterattack these agents is still common, thus, 
combination regimens have become well-established to circumvent cancer resistance (Yu, 2006, 
Cassileth, 1996).   
Statins are low molecular weight drugs derived from fungal fermentation and primarily used in 
the treatment of hypercholesterolaemia and cardiovascular disease. Statins reduce intracellular 
synthesis of cholesterol and in turn, decrease atherosclerotic plaque formation (Hindler, 2006, 
Rignanti, 2011). The mechanism of action of statins are to competitively inhibit the enzyme 3-
hydroxymethyl-3-glutaryl Coenzyme A reductase (HMGCR), which converts HMG-CoA into 
mevalonic acid, a cholesterol precursor in the mevalonate pathway (Stancu, 2001). Statins act in 
a dose dependent manner to compete and alter the conformation of HMGCR, and prevent it 
from attaining a functional structure. 
Atorvastatin (ATO) belongs to the statin drug family and is one of the most prescribed drugs to 
hypercholesteroleamic patients. Recent studies have shown that statins, including ATO, exert 
cholesterol-independent activity including anti-cancer properties. These effects can be explained 
by the drugs’ main function in which they target and inhibit 3-hydroxy-methylgluraryl CoA 
reductase. This inhibition eventually leads to the reduced levels of many downstream products 
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of the mevalonate pathway which play pivotal roles in various cellular signalling pathways 
(Wong, 2002). Statins have proven to trigger cancer cell death in various tumour cells both in 
vitro and in vivo (Hoque, 2008, Hindler, 2006, Wong, 2002), thus creating new avenues in 
cancer therapeutics.  
A hallmark of cancer is the evasion of apoptosis, cell survival and proliferation. These are seen 
by alterations and mutations in key regulators of apoptosis (Cairns, 2011, Wong, 2011). ATO 
has been shown to have synergistic interactions with drugs such as valproic acid (Barros, 2013) 
and gefitnib (Chen, 2013) which induce cell death in malignant cells, however, a clear 
mechanism of cell death in lung carcinoma has not been elucidated.    
This study was designed to explore the cytotoxic effects of ATO on human lung 
adenocarcinoma cells (A549) by investigating molecular events contributing to cell death 
following acute exposure (48 hours) to the commercially used statin, ATO. It was hypothesised 
that ATO induces apoptotic death in cancerous lung cells, thus having dual therapeutic potential 


















1.2 LITERATURE REVIEW 
1.2.1 Lung Cancer 
	  
1.2.1.1 Epidemiology 
Lung cancer is the most common malignancy worldwide and has the highest mortality rate 
among cancers worldwide with approximately 1.61 million new cases each year (Molina, 2008, 
Mukansi, 2014). The mortality rate in South Africa is estimated at 17% of all cancer-related 
deaths and the risk of developing lung cancer is 1 in 20 for black South African males and 1 in 
76 for black South African females (Pacella-Norman, 2002). A study on lung cancer completed 
in Johannesburg, South Africa, showed that adenocarcinoma was the second most common 
malignancy found in black males and white females. Studies also show that the disease is more 
common in men than in women with an estimated ratio of 2:1 (Mukansi, 2014).  
The two most common types of lung cancer includes small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). NSCLC has the highest incidence accounting for 
approximately 85% of diagnosed lung cancers (Molina, 2008). NSLC is made up of different 
cancer cells including squamous cell carcinoma, large cell carcinoma and adenocarcinoma.  
In the search for cancer prevention and treatment, biomedical research requires the use of 
cancerous cells or tumours in order to identify accurate results. However, the use of patient 
tissue samples have increasingly stringent ethical and medical requirements. Thus in vitro 
models have been developed for the experimental studies worldwide.  Human derived cell lines 
have been established to minimize the use of patient tissue samples in the developmental stages 
of testing compound (Gazdar, 2010). 
The A549 cell line was established in 1972 and is derived from human lung adenocarcinoma 
cells. The cells may be characterised by type II pulmonary epithelium containing lamellar 
bodies which has allowed the cell line to be frequently used in toxicology and cancer 
therapeutic studies  (Foster, 1998).  
 
1.2.1.2 Risk factors 
Urbanization as well as lifestyle changes have be associated with the increased incidence of 
lung cancer. Pollution, lack of physical activity and dietary changes have been the catalyst to 
cancer cell metabolism and proliferation (Molina, 2008). The 20th century has seen the 
emergence of a lung cancer epidemic in which cigarette smoking has played a central role. 
Studies have shown that tabacco smoking caused approximately 1.6 % of lung cancers and 
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passive smoking more than doubles the risk of lung cancer in adulthood. Cigarette smoke 
contains a complex mixture of carcinogens such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) nicotine, benzo(a)pyrene, cadmium, and vapours such as formaldehyde and 
ethylcarbamate which can negatively affect cells of the respiratory system (Sexton, 2008). 
Air pollution as well as occupational exposure to hazardous chemicals and carcinogens 
including polycyclic aromatic carbons and crysotile asbestos increase the risk of developing 
lung cancer through oxidative stress, inflammation and the deregulation of the nervous system 
(Pacella-Norman, 2002). Some incidences of lung cancer have been reported repeatedly within a 
family for over 60 years indicating a hereditary basis for the development of the disease. An 
increased risk of lung cancer was seen in TP53 germline sequence carriers and epidermal 
growth factor receptor T790M sequence variations (Molina, 2008). 
1.2.1.3 Treatment   
The treatment methods for lung cancer depends on the stage of development of the tumour and 
the availability of treatment methods. The most common conventional treatments include 
surgery and radiation for early stage cancer before metastasis occurs. The tumour cells may also 
develop resistance to treatment over a prolonged use. Anti-angiogenesis agents and receptor 
tyrosine kinase (RTK) inhibitors are a new targeted therapy which has shown improved 
response rates to different groups of patients with NSCLC (Molina, 2008, Cetintas, 2012).   
Advanced stage cancer patients may undergo palliative chemotherapy (Molina, 2008). Systemic 
anti-cancer therapies, such as chemotherapy, can produce acute and chronic organ damage. 
Chemotherapy targets active cancerous cells, but are also lethal to healthy cells including bone 
marrow suppression as well as ocular, hepatic, cardiac and renal toxicity (Verhoef, 2008). New 
treatment regimens attempt to combat these harmful effects by providing therapy that involves 
aggressive, specific cancer cell death with minimal side effects to the patient (Cassileth, 1996). 
Chemoprevention agents such as dietary supplementation and plant-derived drugs may be used 
in combination with advanced chemotherapeutic drugs to produce a synergistic effect, thus 
enhancing the anticancer activities. Since recurrence of cancer after chemotherapy often occurs, 
new therapies would have to prevent the relapses, delay metastasis, and inhibit any chance of 
tumour growth  (Mehta, 2014). 
 
1.2.2 Statins 
Statins are a class of drugs with a low molecular weight. These drugs are primarily used to treat 
patients diagnosed with hypercholesterolemia and cardiovascular disease. Statins reduce the 
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intracellular synthesis of cholesterol and in turn, decrease atherosclerotic plaque formation and 
stabilize pre-existing atherosclerotic plaques (Hindler, 2006, Rignanti, 2011). Statins are able to 
inhibit the conversion of HMG-CoA to mevalonate due to their action as structural analogues of 
HMG-CoA reductase (Istvan, 2001) 
1.2.2.1 Pharmacology 
Statins derived from fungal fermentation include lovastatin, simvastatin and pravastatin whereas 
the synthetic statin products include fluvastatin and atorvastatin (Figure 1.1) (Chan, 2003). The 
liver is the target organ for these drugs and the bioavailability is limited by extensive first pass 
metabolism. The Cytochrome P450 (CYP450) monooxygenases are located in the endoplasmic 
reticulum (ER), with the liver and small intestine having the highest concentration of CYP450 
enzymes. The enzymes allow for the oxidative metabolism of a wide range of compounds 
including medications. The CYP450 enzymes allow for the biotransformation of statins to polar 
compounds, making excretion possible via the kidney (Guengerich, 1993). The CYP450 
pathways lead to the majority of statins having elevated serum levels, with lovastatin, 













Figure 1.1: Chemical structures of HMG-CoA reductase inhibitors (statins). Simvastatin, 
lovastatin, and pravastatin are derivatives of fungal products as they have a hydronaphthalene 





1.2.2.2 Mechanism of Action 
Statins target hepatocytes and inhibit the enzyme HMGCR, which converts HMG- CoA into 
mevalonic acid, a cholesterol precursor in the mevalonate pathway (Stancu, 2001). Statins act in 
a dose dependent manner to competitively inhibit and alter the conformation of the HMGCR 
enzyme. This prevents the enzyme from attaining a functional structure, hence these drugs are 
very specific and effective. The inhibition of HMGCR eventually leads to the increase in 
hepatic low –density lipoprotein (LDL) and hence low circulating LDL (Figure 1.2). This occurs 
by inducing the splicing of sterol regulatory element binding proteins (SREBPs) by a protease 
from the ER. The SREBPs translocate to the nucleus where they induce gene expression for the 
LDL receptor. The decrease in cholesterol synthesis in hepatocytes leads to a negative feedback 
which increases hepatic LDL receptors which allows for the binding of LDL to these receptors, 



















Statins not only reduce serum cholesterol levels but also mevalonate synthesis and isoprenoid 
metabolites (Figure 1.3) (Pisanti, 2014). This leads to decreased downstream products of the 
mevalonate pathway including dolichol, geranylphosphate (GPP) and farnesylphosphate (FPP). 
Geranylphosphate and farnesylphosphate play a role in a number of cellular processes by acting 
as lipophilic anchors on the cell membrane and allow for the attachment and biological activity 
of proteins from the GTPase family (Cafforio, 2005).  G-proteins Ras and Rho are isoprenylated 
by GPP and FPP. These G-proteins are key regulators of signal transduction of membrane 
receptors involved in cell proliferation, differentiation and apoptosis (Rignanti, 2011). Studies 
have shown that Lovastatin stabilizes cell cycle kinase inhibitors p21 and p27 and leads to cell 
cycle arrest in the G1 phase in breast cancer cell lines. Dolichol has stimulatory effects on DNA 
synthesis and may interact with several tumour cell proteins (Hindler, 2006). Ubiquinone is one 
of the end products of the mevalonate pathway and functions in the production of ATP from the 















Figure 1.3: Mevalonate pathway products are reduced by the inhibition of HMG CoA 
reductase, leading to downstream metabolic effects of cells (Stancu, 2001). 
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1.2.2.3 Pleiotropic Effects of Statins 
The lipid-lowering effects of statins are generally well known, however recent studies have 
shown that statin therapy may have other beneficial aspects independent of its cholesterol-
lowering effects. Tandon et al (2001) expanded on the pleiotropic actions of HMG CoA 
inhibitors including its anti-inflammatory actions, its ability to reverse endothelial dysfunction 
by decreasing LDL oxidation and increasing nitric oxide (NO) availability. The drugs have also 
been shown to modulate vascular remodelling by the inhibition of transcription factors such as  
Nuclear Factor Kappa-B (NFkB) and cellular matrix metalloproteinases (MMP) (Hindler, 
2006).  
The mevalonate pathway for cholesterol synthesis has been implicated in tumorigenesis, with 
studies in the past decade looking at statins as therapeutic agents in cancer by researching the 
anti-proliferative effects of statins with regard to cell cycle arrest and apoptosis (Pisanti, 2014).   
Stancu et al (2001) described the effect statins have on osteoclast formation and bone 
resorption, where recent experimentation showed that Lovastatin inhibited GTP- binding 
proteins which act to control cytoskeletal reorganisation, vesicle fusion and apoptosis, which are 
processes that are involved in osteoclast activation and survival (Stancu, 2001, Lee, 2006). 
1.2.2.4 Adverse effects of Statins 
Statins are generally well endured with the only toxicities observed being liver and muscle 
toxicity. Various hypotheses have been proposed to account for the muscle dysfunction related 
to statin use. Ubiquinone depletion leads to myalgia in patients on statin treatment (Chan, 2003). 
Myopathy can occur if there is co-administration of statins with inhibitors of CYP450 enzymes, 
other inhibitors of statins or inhibitors of statin metabolites. Fibrates and niacin also increase the 
risk of myopathy (Stancu, 2001). Statins have been reported to affect skeletal muscle membrane 
physiology by changing membrane fluidity, Na+/K+ pump density and change in cholesterol 
content. This may lead to changes in calcium concentration resulting in membraneolysis 
(Stancu, 2001, Chan, 2003).   
Stroes et al (2015) elucidated on the deleterious effects of statin therapy on mitochondrial 
function. Biopsies of skeletal muscle from patients on statin therapy showed increased 
intramuscular lipid content, reduced mitochondrial DNA and lower mitochondrial oxidative 
phosphorylation during simvastatin use. Genetic susceptibility to statin-induced myopathy is a 
new research avenue that is being investigated (Stroes, 2015). A study on patients undergoing 
high-dose simvastatin showed that the protein encoded gene, SLCO1B1, which is associated 
with statin toxicity, detected a defective single nucleotide polymorphism (SNP), rs4149056, in 
disequilibrium with the c_521T_C SNP. It was seen that in homozygotes, the SNP was 
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associated with an 18% risk of muscle symptoms compared with heterozygotes, in those 
without risk alleles, the risk of muscle symptoms were 0.6% (Stroes, 2015).    
 
1.2.3 Statins: Potential in Cancer Therapy 
 
Statins have been well described to be anti-atherosclerotic, anti-thrombic and anti-inflammatory 
in both in vitro and in vivo models. Hindler et al (2006) suggested that statins may also have 
anti-proliferative, anti-angiogenic and anti-metastatic properties which would lead to a novel 
therapeutic approach to cancer treatment and even prevention (Hindler, 2006). 
In recent years, increasing evidence from in vitro and in vivo studies have established the anti-
tumour activity of statins, independent of cholesterol reduction. These anti-tumour properties 
have been seen in prostate (Lee, 2006), colon (Agarwal, 1999), leukaemic (Xia, 2001), 
pancreatic (Kusama, 2001) and breast cancer cells (Denoyelle, 2001).  Studies have also been 
done on the effects of statins on normal cells. Gauthaman et al (2007) showed that cell 
proliferation of ovarian and colon cancer was inhibited by simvastatin, lovastatin, and 
mevastatin, whereas normal embryonic stem cell growth was not affected by all of these four 
statins (Gauthaman, 2007).  Preclinical studies have demonstrated that lipophilic statins such as 
lovastatin and atorvastatin have better anti-tumour activity, relative to hydrophobic statins such 
as pravastatin.  This is logical since lipophilic statins are more accessible to tumour cells 
(Cafforio, 2005).    
Hoque et al (2008) showed that statins may trigger different tumour cells to undergo apoptosis 
in vitro and supress tumour growth in vivo (Hoque, 2008). This was also expressed by Hindler 
et al (2006) which described experiments where statins inhibited tumour growth and induced 
apoptosis in various malignancies including neuroblastoma, glioma and leukaemic cell lines 
(Hindler, 2006). 
The reduction of sterol synthesis by statins suggest that inhibition of tumour growth may be 
related to the reduction of non-steroidal isoprenoid compounds. This inhibits Ras dependent 
tumour cell growth due to the decrease in farnesylphosphate production. Mevalonate also plays 
a key role in cell proliferation, and malignant cells have increased HMG CoA reductase activity 
(Stancu, 2001). This information suggests that statins can selectively inhibit tumour growth and 




1.2.3.1 The apoptotic effects of Statins: 
Statins affect the lipid raft in the plasma membrane. These hydrophobic molecules are involved 
in signal transduction of processes such as migration, growth and survival. Hoque et al (2008) 
showed that statins were able to initiate apoptosis in different tumour cells in vitro and inhibited 
growth of tumours in vivo. Wong et al (2002) described tumour specific apoptosis due to statins 
after performing experiments on both primary and derived cell lines (acute myeloid leukemia 
(AML), myeloid progenitor cells from bone marrow and blood and non-transformed 
hematopoietic cells). Lovastatin induced apoptosis in the AML cells but the progenitor cells and 
non-transformed cells did not undergo apoptosis and retained their full proliferative potential 
(Wong, 2002).  
Studies also show that statins mediate apoptosis by upregulating pro-apoptotic proteins such as 
Bax and Bim, and downregulate anti-apoptotic proteins Bcl-2 and Bcl-x. Lovastatin increased 
Bim protein expression and induced programmed cell death in glioblastoma cells, with similar 
effects on prostatic epithelium and leukaemic cells through the activation of caspases 3 and 7 
(Hindler, 2006). Other studies showed apoptosis to be mediated through the depletion of GPP. 
Xia et al (2001)  reported that mevalonate and GPP reversed the cellular apoptosis induction of 
lovastatin in acute myeloid leukaemia cells, indicating the inhibition of geranylgeranylation of 
target proteins is an important mechanism of lovastatin-induced apoptosis (Xia, 2001). Pisanti et 
al (2014) described the initiation of apoptosis via the inhibition of Ras-MAPK and PI3K/AKT 
pathways, thus regulating anti- and proapoptotic mRNA and protein levels (Pisanti, 2014). 
1.2.3.2 The Anti-Proliferative effects of Statins 
Chan et al (2003) elucidated that statins are able to synchronize tumour cells by blocking the 
transition in the cell cycle from the G1 to S phase. This was reversed by mevalonate. It was also 
found that the inhibition of cell growth by Lovastatin did not depend on Ras function (Chan, 
2003). Recent studies have shown that cell cycle arrest is mediated by an increase in cyclin 
dependent kinase inhibitors, p21waf1/AP1 and p27KIP, in which degradation is reliant on Rho 
GTPases. Statins decrease the isoprenylation of Ras and Rho proteins due to the inhibition of 
GPP and FPP isoprenoids. Ras and Rho proteins are able to bind to and hydrolyse GTP and thus 
activate downstream effectors such as serine-theronine kinases, NFkB, Stress-activated protein 
kinases- jun amino-terminal kinases (SAPK-JNK), PI3K and Ras-MAPK pathways and 
eventually lead to cell proliferation. By the inhibition of Ras and Rho proteins, statins may thus 




The mevalonate pathway for cholesterol biosynthesis and protein prenylation has been found to 
initiate many aspects of tumour progression. Statins therefore play a beneficial role in cancer 
research. The optimal regimen for statin therapy however has not yet been defined. Statins, 
alone, are not effective anticancer agents, but in combination with other cytotoxic agents, 
preclinical as well as clinical data shows that statins may enhance the effect of 
chemotherapeutic agents (Hindler, 2006). In conclusion, it may be said that statins are the new 
stepping stone to cancer therapy.   
1.2.4 Apoptosis: Programmed Cell Death 
 
Daily billions of cells are subjected to programmed cell death in order to maintain optimal 
functioning of an organism. The regulation of the number of cells in these organisms are very 
important and follow a chain of events that finally lead to the process of apoptosis. Apoptosis 
was first described in 1972  (Kerr, 1972). Programmed cell death may be characterized by its 
distinct morphological characteristics as well as its energy-dependent nature.  Apoptosis occurs 
through normal aging and development and can also occur as a defence mechanism in the 
immune system (Elmore, 2007).  
A group of aspartate- specific cysteinyl proteases referred to as caspases execute apoptosis. 
These caspases are expressed as inactive zymogens that are proteolytically activated following a 
stimulus (Rastogi, 2009). There are two distinct groups, the initiator and activator caspases 2, 8, 
9 or 10 which allow for the cleavage and activation of a second group of caspases being the 
effectors or executioner caspases 3 or 7 which allow for the initiation of apoptotic cascade 
(Johnstone, 2002, Fischer, 2006).  
During the process of apoptosis, cell shrinkage is an early morphological feature. When the cell 
shrinks, it allows for the organelles to become tightly packed and the cytoplasm to become 
dense. Chromatin condensation is a common feature seen in apoptosis and is known as 
pyknosis. The plasma membrane then begins to form blebs and separate in apoptotic bodies. 
These bodies are then phagocytosed by macrophages and parenchymal cells and degraded 
within phagolysosomes (Elmore, 2007).     
There are two major apoptotic pathways that exist in mammalian cells, the extrinsic death 
receptor-mediated pathway and the intrinsic mitochondrial/p53-mediated pathway (Figure 1.2). 
Both pathways require constant control and regulation and require a constant supply of energy 


















Figure 1.4: Overview of the extrinsic and intrinsic apoptotic pathways (Wong, 2011). 
 
1.2.4.1 The Extrinsic Apoptotic Pathway 
The extrinsic apoptotic pathway or death receptor pathway makes use of transmembrane death 
receptor-mediated reactions which involve the tumour necrosis factor (TNF) –α family of death 
receptors including CD95, TNF receptor and TRAIL receptor. Receptors of the family share a 
domain which is cysteine rich with a domain known as the death domain. The function of the 
death domain is to transfer death signals from the cell surface to the inside of the cell.  Ligation 
of the transmembrane death receptors initiate this pathway. Fas-L/Fas R recruit Fas associated 
protein with the death domain FADD, TNF/TNF-R recruits TNF-R1 associated protein with the 
death domain TRADD with FADD. Dimerization of a death effector domain (DED) then occurs 
and FADD is able to communicate with procaspase 8 and form a death inducing signalling 
complex (DISC) which results in the cleavage and the activation of caspases 8. The executioner 
caspases are then activated and apoptosis is initiated (Fulda, 2006, Hsu, 1995, Johnstone, 2002).  
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Rastogi et al (2009) also mentioned FLIP as an inhibitory molecule in the activation of caspase 
8. FLIP is a caspase 8 homolog that binds to FADD and caspase 8, rendering them inactive and 
inhibiting death receptor-mediated apoptosis (Rastogi, 2009). 
1.2.4.2 The Intrinsic apoptotic Pathway 
The intrinsic apoptotic pathway consists of a diverse series of intracellular mediators in which 
mitochondria play a significant role in, resulting in the activation of the caspase pathway and 
eventually leading to the execution phase of apoptosis and cell death (Fulda, 2006).  
The permeabilisation of the inner mitochondrial membrane is a crucial step in the intrinsic 
pathway for the release of apoptotic proteins. The loss of mitochondrial transmembrane 
potential is due to the regulation of two Bcl-2 family members by transcription factor p53. P53 
inhibits the anti-apoptotic protein Bcl-2 and activates cytosolic Bax, which becomes 
oligomerised and forms mitochondrial membrane permeability transition pores. The release of 
apoptogenic molecules, Cytochrome c and serine protease HtrA2/Omi then occur which brings 
about the formation of the apoptosome which is made up of Cytochrome c, apoptotic protease 
activating factor 1(Apaf1) and procaspase 9.  Cytochrome c binds the closed inactive form of 
Apaf-1, forcing it into its open active conformation. This frees the N-terminus of Apaf-1, which 
is normally bound and inhibited by WD-40 repeat region, allowing Apaf-1 to bind and activate 
procaspase-9 (Fulda, 2009).The clustering of procaspase 9 leads to the activation of caspases 9 
which in turn activate the executioner caspases (Elmore, 2007, Wang, 2001).    
1.2.4.3 Caspase Independent Apoptosis: 
Caspase independent apoptosis was first seen in the human Jurkat cell line, where the inhibition 
of caspases did not inhibit Bax-induced cell death but it did change the morphology of the dying 
cell (Broker, 2005). Evidence now shows that programmed cell death can occur in the absence 
of caspases and be induced by non-caspase proteases. Different cell organelles have been 
implicated in contributing to cell death in a caspase-independent manner with the mitochondria 
playing a central role by releasing death executors from the intermembrane space to the cytosol, 
triggering the death of the cell (Rieckher, 2010).  
Other proteins involved in caspase-independent apoptosis include endonuclease G and 
Apoptosis inducing factor (AIF). Endonuclease G is a mitochondrial enzyme that is able to 
execute caspase-independent DNA fragmentation in nuclei. The enzyme is able to interact with 
DNase I to generate internucleosomal DNA fragments during oxidative stress conditions (Bajit, 
2006). Another mitochondrial protein that plays an important role in apoptosis is AIF which is 
normally found in the intermembrane space of the mitochondria where it undergoes an 
oxidoreductase function. (Broker, 2005). Calpains are proteases that are normally found as 
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inactive zymogens in the cytosol but during ER stress, they are released and play a role in 












Figure 1.5: Crosstalk between organelles during cell death which may be triggered dependent 
(intrinsic apoptotic pathway) or independent of caspase (Broker, 2005). 
 
1.2.4.4 P53 and Apoptosis  
Transcription factors act to maintain tissue homeostasis and control the number of cells within 
an organism (Fridman, 2003). The p53 tumour suppressor protein has been extensively studied 
and found to be a regulator of many cellular processes including apoptosis. P53 halts the cell 
cycle to repair the damage to cell’s DNA or allow for apoptosis during hypoxic conditions or 
mutagenic oncogene expression. Mutations in the TP53 gene lead to a mutant form of the gene 
that is unable to regulate cell growth and division effectively, thus resulting in the continued 
survival and proliferation of damaged cells. In cancer cells, this trait is well established as there 
is common dysregulation of the p53 transcription factor (Fridman, 2003).  
Previous studies have described p53 as a mediator of cell fate depending on stress, cell type, 
tissue and other cofactors. The ‘affinity model’ was created to expand on the outcome of p53 
activation and it proposed that low p53 levels bind to high affinity p53 response elements in 
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pro-arrest genes and vice versa where high levels of p53 is needed to bind to low affinity 
response elements in pro-apoptotic genes (Kracikova, 2013). 
Approximately 50% of human cancers have p53 mutations but it is seen that the remaining 50% 
can elucidate p53 as a major target for anti-cancer drug development (Wang, 2012). Proteins 
that sense DNA damage such as Checkpoint Kinase 2(CHK2) and  Ataxia telangiectasia 
mutated (ATM) phosphorylate and stabilize p53 and inhibit its mouse double minute 2 homolog 
(MDM2)-ubiquitination and degradation (Johnstone, 2002, Wang, 2012). P53 may be 
phosphorylated at different sites by multiple kinases. Phosphorylation of p53 at serine 46 
regulates the ability of p53 to induce apoptosis, whereas phosphorylation at serine 392 regulates 
the cell cycle (Ashcroft, 1999). 
P53 functions as a master regulator in the mitochondrial dependent apoptotic pathway by 
transcriptionally activating Bcl-2 proapoptotic proteins and inhibiting anti-apoptotic proteins 
such as Bcl-2 and IAPs (Figure 1.6). It can also transactivate other apoptotic proteins such as 
phosphatase and tensin homolog (PTEN), p53 apoptosis effector related to PMP-22 (PERP) and 







Figure 1.6: p53 regulation in the mitochondrial/ intrinsic apoptotic pathway (Prepared by 
Author). 
1.2.4.5 Bcl-2 and Bax regulation of Apoptosis: 
The Bcl-2 family of proteins act as key regulators of mitochondrial-dependent apoptosis and the 
mitochondrial outer membrane permeability pore.  The Bcl-2 family are divided into three 
groups, the pro-apoptotic multidomain, anti-apoptotic/pro-survival proteins and the pro-
apoptotic BH3 only proteins. All members of the family have one or more homology domains 
which are labelled as the Bcl-2 homology (BH 1, 2, 3 and 4). This homology allows for the 
interaction between the members of the family (Ola, 2011).   
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Bcl-2 is an anti-apoptotic or pro-survival protein that contains a carboxy-terminal hydrophobic 
transmembrane tail domain, this domain allows it to remain within the outer mitochondrial 
membrane. The protein acts to inhibit the characteristic features of apoptosis by inducing 
survival mechanisms by various stimuli which prevent mitochondrial outer membrane 
permeability. Bcl-2 also binds to and inactivates pro-apoptotic proteins to inhibit the 
downstream events of apoptosis. Bcl-2 associated X protein (Bax) is a proapoptotic protein that 
lies dormant in the cytosol by interactions with various proteins such as humanin peptides. The 
activation of Bax leads to the exposure of the N-terminus of the protein which cause a 
conformational change and the formation of homo-oligomers. These oligomers produce pores in 
the outer mitochondrial membrane and constitutes a change in mitochondrial membrane 
potential leading to the release of pro-apoptotic molecules from the formed pores (Ola, 2011, 
Elmore, 2007, Johnstone, 2002).   
1.2.4.6 Smac/DIABLO regulation of Apoptosis: 
Second mitochondria-derived activator of caspases/Direct inhibitor of Apoptosis-Binding 
Protein with Low pI (Smac/DIABLO) is a 25-kDa mitochondrial protein which is released from 
the mitochondria during apoptosis (Wang, 2001). This nuclear encoded protein is able to 
translocate into the mitochondria. During the transition, the N-terminus is removed by 
proteolysis, producing an activated form of the molecule. The activated Smac/DIABLO exists 
as a dimer, mediated by a hydrophobic interface within the N-termini of the individual 
molecules (Adrain, 2001).  
Smac/DIABLO neutralizes inhibitor of Apoptosis proteins (IAPs), particularly interacting with 
the Baculovirus inhibitor of Apoptosis protein repeat (BIR) domains of X-linked inhibitor of 
apoptosis protein (XIAP).  A particular NH2- terminal motif, consisting of four amino acids 
(Alanine-Valine-Proline- Leucine) is responsible for the interaction with IAPs.  This allows for 
the release of caspases -9 and -3 (Martinez-Ruiz, 2008). Martinez- Ruiz et al (2008) also stated 
that during cancer cell progression, lower Smac/DIABLO levels are seen and hence higher 
apoptosis resistance occurs (Martinez-Ruiz, 2008).    
 
1.2.4.7 Oxidative stress in cancer and apoptosis: 
Reactive oxygen species (ROS) are classified as oxygen-containing chemical species with 
reactive properties. The molecules are derived from oxygen used in metabolic reactions in the 
mitochondria, endoplasmic reticulum and the peroxisomes (Gorrini, 2013).  
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Cancer cell metabolism makes use of anaerobic glycolysis, which is termed as the Warburg 
effect (Heiden, 2009). This allows for the production of ROS from signal transduction and 
transcription factors (Gorrini, 2013, Noda, 2001).  ROS and cell transformation in cancer cells 
were first established in 1981 and showed cancer cells to have a constant demand for ATP 
production and thus an accumulation of ROS which have different roles in the cell metabolism 
depending on the amount being produced (Gorrini, 2013).  
ROS have very high chemical reactivity and affect cellular DNA, phospholipids, carbohydrates 
and proteins, resulting in protein oxidation and degradation as well as lipid peroxidation. 
Oxidative stress can lead to DNA damage by the modification of purine and pyrimidine bases 
leading to strand breaks. ROS react with DNA to form a range of cytotoxic oxidative base 
lesions, including 7, 8-dihydro-8-oxoguanine (8-oxoG). This oxidative base lesion is different 
from guanine as it pairs incorrectly with adenine, eventually leading to transversion mutations 
(Youn, 2007). Alterations in DNA sequences may alter and/or activate several proto-oncogenes 
and cause mutations in tumour suppressor genes such as p53 and cell-cycle related genes 
(Mátes, 2012, Noda, 2001).  High levels of ROS generation in response to external stimuli lead 
to the activation of transcription factors which initiate apoptosis by caspases. ROS-­‐induced	  DNA	  
damage	  allows	  for	  the	  activation	  of	  p53	  which	  allows	  for	  the	  modulation	  of	  programmed	  cell	  
death	  and	  cell	  cycle	  arrest.	  Pro-­‐apoptotic	  proteins	  Bax	  and	  Fas	  ligands	  allow	  for	  the	  initiation	  
of	  apoptosis	  through	  sequential	  events	   leading	  to	  the	  activation	  of	  caspases.	  Bcl-­‐2	   is	  an	  anti-­‐














Figure 1.7: The induction of apoptosis due to ROS (Prepared by author). 
 
1.2.4.7.1 Antioxidant response to Reactive Oxygen Species: 
In normal cell metabolism, oxidizing equivalents in the form of ROS are generated during 
cellular respiration in the electron transport chain. Mitochondrial superoxide is the primary 
source of ROS produced. The formation of superoxide occurs due to the leak of electrons from 
the ETC at complexes I and II. Under normal conditions, complex IV reduces oxygen to form 
hydrogen peroxide, however, if a single electron is transferred to a dioxygen molecule at other 
points, superoxide may be formed, thus increasing oxidative stress levels (Jastroch, 2010).  The 
cell’s defence mechanism against increased oxidative stress is the production of antioxidants 
which act as reducing equivalents leading to a redox balance (Davis, 2000).   
These antioxidants play a role in the removal of free radicals and protect the cell from oxidative 
damage (Valko, 2006). The transcription factor, nuclear factor erythroid 2 (Nrf2), which is 
found in the cytosol, is bound to Kelch-Like ECH- Associated Protein 1 (Keap 1) to form a 
complex keeping Nrf2 inactive. When ROS levels rise, oxidation of the cysteine residues 
binding Nrf2 to Keap1 facilitates the dissociation of Nrf2 from Keap1, allowing Nrf2 to 
translocate to the nucleus, where it exerts its activity. As seen in Figure 1.8, upon recognition of 
a consensus sequence, Nrf2 binds to the antioxidant response element (ARE), initiating the 
transcription of multiple antioxidant genes (Shih, 2005). Nrf2 is able to regulate the production 
of the endogenous antioxidant, reduced glutathione (GSH). In highly oxidative environments, 
hydrogen peroxide (H2O2) is able to oxidize GSH to glutathione disulphide (GSSG), thereby 























Figure 1.8: The Keap-Nrf 2 pathway- Regulation of antioxidant gene production by the 
activation and translocation of Nrf2 to the nucleus of the cell after dissociation from Keap1 
(Mitsuishi, 2012). 
 
1.2.4.8 The role of DNA Repair Enzymes PARP and OGG1 in Apoptosis: 
Poly (ADP-ribose) polymerase-1 or PARP-1 catalyses the poly-ADP-ribosylation of specific 
nuclear proteins in order to repair DNA strand breaks and overall genomic maintenance. PARP-
1 is the most abundant and well characterized enzyme of the PARP family. The enzyme consists 
of three conserved major domains, being, a NH2 –terminal DNA-damage sensing and binding 
domain containing three zinc fingers, a C-terminal catalytic domain and an auto-modification 
domain. The zinc fingers play an important role in the activation of PARP1 with zinc 1 and 3 
participating in the DNA-dependent activation of the enzyme.  
When DNA breaks occur, as seen in Figure 1.9, PARP-1 is activated and cleaves nicotinamide 
adenine dinucleotide (NAD+) to yield nicotinamide and ADP. The addition of ADP-ribose units 
together form a long branched chain attached to PARP-1, histones and other DNA repair 
proteins which form a polymer adjacent to the strand breaks. The polymer forms a scaffolding 
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and recruit other proteins that are critical to DNA repair including proteins involved in 
chromatin remodelling and chromosomal organisation (Javie, 2011).     
In the late stages of Apoptosis,  PARP1 is cleaved into 89 and 24 kDa fragment, thus 
inactivating the enzyme  (Boulares, 2013, DÁmours, 2001). Javie et al (2011) discussed, in 
depth, the role of PARP inhibitors (PARPi) as chemotherapeutic agents. The cytotoxic agent 
contains analogues that are able to inhibit PARP1/2 and lead to the accumulation of damaged 
DNA, overwhelming alternative repair pathways and ultimately leading to cell death. Most 
PARPi are undergoing different phases of clinical trials (Javie, 2011). 
 











Figure 1.9: Catalytic activity of PARP-1. Cleavage of NAD+ by PARP-1 allows for the 
formation of polymers which recruit and activate repair pathways for the single-stranded DNA 
breaks (SSB) (Javie, 2011). 
 
Ineffective repair of damaged mitochondrial DNA due to oxidative stress may lead to 
mitochondrial dysfunction and apoptosis (Liu, 2011). 8–Oxoguanine glycosylase (OGG1) is a 
base excision repair enzyme which plays an important role in eukaryotes by allowing for repair 
to DNA in both the nuclear and mitochondrial genomes, thereby suppressing cell death (Youn, 
2007). DNA base excision repair (BER) makes use of a four-step pathway (Figure 1.10). The 
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initial steps are the recognition of oxidative-damaged bases by OGG1, followed by the repair of 
the aberrant bases by Ape1/Ref1. OGG1 has two enzymatic functions: glycosylase and lyase 
activity. The glycosylase activity cleaves the C1 glycosidic bond between the base and ribose 
sugar, this allows for the removal of the oxidized guanine and creates a vacant area next to 
cytosine, OGG1 then nicks the phosphodiester backbone between the C3 bond of the ribose ring 
and the phosphate on the 3’side of the vacant area. This results in the single stranded break. 
Ape1 can then removes the residual ribose phosphate and produces 3’hydroxyl group (OH) 
which may be extended by DNA polymerase- β (McMurray, 2010). A new base is then inserted 
and the damaged strands are re-ligated by a DNA ligase (Liu, 2011). 
Liu et al (2001) also stated that the overexpression of mitochondrial targeted OGG1 prevents 
mitochondrial DNA damage and the intrinsic apoptotic pathway in vascular endothelial and 
asbestos-exposed cells (Liu, 2011). This suggests that the intrinsic apoptotic pathway may be 











Figure 1.10:  OGG1 repair of 8-oxoG via DNA base excision repair pathway (BER) (adapted 
from (Ba, 2014)). 
 
1.2.5 The Evasion of Apoptosis by Cancer Cells: 
Cancer originates from a single cell. Carcinogenesis, the process in which a normal cell 
becomes a malignant cell, constitutes multiple complex molecular signalling pathways. The 
process of carcinogenesis may be defined by three processes i.e., initiation, promotion and 
22	  
	  
progression. Initiation occurs when a normal cell is transformed by gene mutations and altered 
metabolism to an initiated cell (Yokota, 2000). This altered metabolism exhibit different 
characteristics of normal cell metabolism, whereby, lactate is produced from glucose in aerobic 
conditions. This phenomenon was founded by Ota Warburg and is termed, the “Warburg’’ 
effect (Cantor, 2012). Then, the initiated cell undergoes tumour promotion and turns into a pre-
neoplastic cell, which subsequently develop to a neoplastic cell after progression stage (Yokota, 
2000). The stage of promotion is characterized by uncontrollable cellular signalling pathways 
that manifest cell proliferation and alter programmed cell death (apoptosis). 
Apoptosis is involved in the tissue homeostasis which may be characterized by the balance of 
proliferation versus cell death. Apoptotic dysregulation leads to cell survival and tumour growth 
(Fulda, 2006). 
Malignant cells contain three major metabolic necessities:- ATP generation, increases in 
biosynthesis of macromolecules being carbohydrates, proteins, lipids and nucleic acids and 
lastly to alter intracellular reactive oxygen species (Cairns, 2011).  Cancerous cells are able to 
alter and mutate key regulators of apoptosis, thereby maintaining survival and allowing for the 
proliferation of the cells (Figure 1.11). 
In the extrinsic pathway, studies have shown that cancer cells have impaired death receptor 
surface expression as an adaptive cell response, this can be seen by a downregulation of CD95 
expressed in neuroblastoma cells and colon carcinoma cells resistant to TRAIL-induced cell 
death (Fulda, 2006). Decoy receptors are also synthesized by cancer cells so that ligand binding 
cannot occur, hence the execution of apoptosis cannot occur. Cancer cells have also been shown 
to increase the expression of anti-apoptotic proteins Bcl-2 compared to that of pro-apoptotic 
proteins such as Bax and Bak. Studies show that these proteins are regulated by ROS production 
as Bcl-2 is localised to the mitochondrial membrane, nuclear envelope and ER. Cytochrome C 
regulates apoptosis when oxidized cytochrome C induces apoptosis and the reduced form of the 
molecule inhibits the programmed cell death (Wong, 2011, Fulda, 2006). Tumour resistance to 
apoptosis may also be caused due to aberrant IAPs. The translation of XIAP and cIAP1 are via 
internal ribosome entry sites (IRES) which allows for translation of the proteins even under 
stress conditions when protein synthesis is usually shut down (Fulda, 2009). Fulda (2009) also 
stated that IRES-mediated translational regulation of XIAP and cIAP1 enables a rapid response 
to transient cellular stress conditions in order to delay cell death and ensure survival of the cell 
(Fulda, 2009).  
Cell proliferation in normal cells is a highly regulated process controlled by checkpoints and 
proteins of the cell cycle. The G0 /resting phase of the cell cycle is important as antigrowth 
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signals exert their influence to block cell proliferation in aberrant cycles. Most cancer cells are 
able to evade this checkpoint and inhibit normal growth suppression in order to continue 
proliferation. The two tumour suppressors most commonly mutated in cancer cells are P53 and 
retinoblastoma protein. Retinoblastoma (Rb) is found at a checkpoint at the G1 phase whereby it 
restricts cell passage to the next phase. Cells with mutated Rb inhibit this regulation and allow 
ongoing cell proliferation (Collard, 2012). P53 acts as a central regulator of apoptosis and 
arrests cell cycle due to DNA damage. Aberrant p53 allows the progression of the cell cycle 
despite DNA damage and cellular stresses (Fridman, 2003). 
 
 






















1.3 AIM AND OBJECTIVES 
 
Hypothesis: 
It may be hypothesized that ATO does not have any effect on human lung adenocarcinoma cells 
(A549). 
Aim: 
To determine the cytotoxic effects of ATO on human lung adenocarcinoma cells (A549) by 
investigating molecular events contributing to cell death following acute exposure after 48 
hours. 
The objectives of the study were to determine: 
o The effect of ATO on cell viability and respiratory output in human lung carcinoma 
A549 cell viability using the MTT assay. 
o The oxidative status of A549 cells exposed to ATO by quantification of the biomarker 
of malondialdehyde (MDA) using the TBARS assay, and to assess the endogenous 
antioxidant response (glutathione and Nrf2).     
o The apoptotic pathways induced using ATO by luminometric quantification of caspase 
(8/9/3/7) activity, and protein expression of apoptotic markers (BCl2, Bax, p53, 
SMAC/DIABLO) via western blot.   
o DNA integrity following ATO administration in A549 cells by assessing DNA 
fragmentation via the comet (SCGE) assay, DNA repair enzymes PARP-1 and OGG1, 











CHAPTER 2-  




The A549 cells were purchased from Highveld Biologicals (Johannesburg, SA). Cell culture 
reagents were purchased from Whitehead Scientific (Johannesburg, SA). Western blot reagents 
were purchased from Bio-Rad (Hercules, CA, USA). CellTitre Glo GSH-Glo Caspase -8, -9 and 
-3/7 Glo luminometry assays were purchased from Promega. All other reagents and 
consumables were purchased from Merck (SA), unless stated otherwise. 
2.2 Atorvastatin Preparation: 
 
A 1mg/ml stock solution was prepared by dissolving 2 x Aspavor20 (20mg Atorvastatin) tablets 
(A39/7.5/0018- Pfizer, Johnnesburg, SA) in 40ml of 0.1M phosphate-buffered saline (PBS). 
Subsequent treatments were diluted from stored stock solution (4°C).  
2.3 Cell Culture and Exposure Protocol: 
 
The A549 cells were cultured (37°C, 5%, CO2) in complete culture media (CCM) [Eagle’s 
minimum essential medium supplemented with 1% L-glutamine, 1% penstrepfungizone and 
10% foetal bovine serum]. Following the determination of the concentration of half maximum 
inhibition (IC50), all treatments for subsequent assays, with the exception of the MTT assay, 
were conducted in 25cm3 sterile cell culture flasks for a duration of 48 hours (h). 
 
2.4 MTT Assay: 
 
2.4.1 Introduction- 
Methylthiazol tetrazolium is a yellow water-soluble tetrazolium dye, that when reduced by 
viable cells turns into a purple water insoluble formazan product. This technique is useful for 
cells that are metabolically active based on their redox potential and capacity of dehydrogenase 
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enzymes to convert yellow water-soluble salt into the formazan product, thus the colour 
function is a useful marker of only viable cells (Figure 2.1). The reaction depends on enzymes 
that catalyse the transfer of electrons to an oxidant compound. The tricarboxylic acid (TCA) 
cycle contains molecules such as NADH/ NADPH/ FADH which are oxidized to NAD+/ 














The cytotoxicity of ATO in A549 cells was measured by the MTT assay. Cells (15,000 
cells/well) in 4 replicates were seeded in a 96-well microtitre plate and allowed to attach 
overnight (37°C, 5% CO2). Cells were then subject to treatment with a range of ATO 
concentrations (0-150µg/ml). Following a 48h incubation, the cells were incubated (37°C, 4h) 
with MTT substrate (5mg/ml in 0.1M PBS). Thereafter, supernatants were aspirated and cells 
were incubated in dimethyl sulphoxide (DMSO; 100µl/well) for 1 h. Optical density (OD) was 
then measured at 570nm, with a reference wavelength of 690nm by an enzyme-linked 
immunosorbent assay (ELISA) plate reader (Bio Tek µQuant, USA). The percentage cell 
viability was calculated by utilising the equation below and a concentration- response curve was 
plotted using GraphPad Prism V5.0 software (USA).	  	  Each experiment was conducted twice on 
separate occasions in order to confirm the data results from the first set matched the repeated 
experiment. The IC50 was calculated. For subsequent assays, A549 cells were treated at 80% 
confluency with an IC50 of 39.25µg/ml for 48 h.  
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% Cell viability =    mean absorbance of treated cells         x 100   
                                 mean absorbance of control cells 
2.5 ATP Assay:  
 
2.5.1 Introduction- 
ATP is a complex nano-machine that serves as the primary energy currency of the cell and is the 
most widely distributed high-energy compound within the human body, thus its production is 
essential for living organisms. The mitochondria is known as the cell’s “power house,” where 
cellular energy is produced in the form of ATP.    
ATP may be produced via glycolysis or cellular respiration, there are three subways pyruvate 
oxidation, the tricarboxylic acid (TCA) cycle and the electron transport chain (Figure 2.2). The 
highest amount of ATP is produced in the electron transport chain via oxidative phosphorylation 













Figure 2.2: Schematic representation of glycolysis, TCA cycle and the electron transport chain. 
All pathways converge and cofactors are transported from one pathway to the other to allow for 






2.5.2 Protocol-  
Adenosine triphosphate (ATP) was measured by the luminometric Cell Titer-Glo® assay 
(G775A, Promega, Madison, Wisconsin, USA). The assay was independently conducted twice.  
The ATP quantification assay utilises bioluminescence to ascertain ATP levels in cells. The 
assay is based on the conversion of a luciferase-inactive derivative by ATP in the presence of 
magnesium ions to D-luciferin. D-luciferin, a luciferase substrate, reacts with the enzyme 
luciferase to produce oxyluciferin and release energy in the form of luminescence (Figure 2.3). 
This luminescent signal is directly proportional to the concentration of ATP present in the cells. 
Cells were seeded in triplicate in a white microtitre plate (20,000 cells per well) in a 1:2 ratio 
with ATP Cell Titer-Glo Reagent. The plate was incubated for 30-min at RT. Luminescence 
was measured on a Modulus™ microplate luminometer (Turner BioSystems, Sunnyvale, 
California, USA). Luminescence is proportional to ATP concentration and was expressed as 
















Figure 2.3: The luciferase reaction in the presence of magnesium, ATP and molecular oxygen 
(Adapted from (Govender, 2012)). 
 
2.6 Lactate Dehydrogenase (LDH) Assay: 
 
2.6.1 Introduction- 
Lactate dehydrogenase is a cytoplasmic enzyme that is found in all major organ systems. In the 
final step of anaerobic glycolysis, the enzyme allows for the transfer of hydrogen, which 
catalyzes the oxidation of L-Lactate to pyruvate with nicotinamide-adenine dinucleotide 
(NAD+) as the hydrogen acceptor. The reaction is reversible, but favours the reverse reaction of 
pyruvate to lactate. Activity of LDH is present in almost all cells of the body and is an 
exclusively cytosolic enzyme. During cell damage, LDH leaks out of the compromised cell 
membrane into the extracellular space (Figure 2.4), thus extracellular LDH levels are a marker 
of cell death or damage due to a wide range of factors including ischaemia, dehydration and 











Figure 2.4: Schematic representation of compromised cell membrane. Lactate Dehydrogenase 
which is primarily found in the cytoplasm leaks into extracellular space during cell damage 
(Prepared by Author). 
2.6.2 Protocol- 
The LDH cytotoxicity detection kit (Roche, Mannheim, Germany) was used to measure cell 
death/damage of ATO treated A549 cells. A colorimetric assay was conducted twice on separate 
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occasions for the quantification of LDH activity in the supernatant of samples. The assay is a 
two-step enzymatic reaction where NAD+ is reduced to NADH/H+ by the conversion of lactate 
to pyruvate. Thereafter, a diaphorase catalyst transfers H/H+ from NADH/H+ to a tetrazolium 
salt to yield a formazan product. To measure LDH activity, supernatant (100µl) was transferred, 
in triplicate, into a microtitre plate in triplicate. Thereafter, substrate mixture (100µl) containing 
catalyst (diaphorase/NAD+) and dye solution (INT/sodium lactate) from the kit was added to the 
supernatant and allowed to react at ambient temperature for 25 minutes. Optical density of the 
resulting formazan product was measured at 500nm with an ELISA plate reader (Bio-Tek 
uQuant). Results are represented as mean optical density. 
2.7 Glutathione Assay: 
 
2.7.1 Introduction- 
When there are increased reactive oxygen species in cells, endogenous antioxidants counteract 
the effects of oxidative stress. Glutathione (GSH) is the one of the most powerful antioxidant 
and detoxifying agents in all human cells due to its protective abilities against radical damage. It 
is a small protein molecule composed of three amino acids: cysteine, glutamate and glycine, 
called GSH precursors or building blocks. The anti-oxidant tripeptide plays an important role in 
the detoxification of peroxides and electrophilic species. Glutathione exists both in a reduced 
(GSH) and oxidized (GSSG) state. The thiol group of cysteine is able to donate a reducing 
equivalent, catalysed by glutathione peroxidase, to detoxify peroxides. Peroxynitrite, hydroxyl 
radical and lipid peroxy-radicals are also detoxified by glutathione. When an electron is 
donated, GSH is oxidized to GSSG which is more reactive. GSH can be regenerated from 
GSSG by the enzyme glutathione reductase (Powers, 2008). NADPH and FAD act as cofactors 










Figure 2.5: Detoxification of H2O2 by glutathione-S-transferase and the regeneration of 




The GSH-Glo™ Glutathione assay (V6911, Promega) was utilized to quantify intracellular 
GSH levels. Subsequent to treatment of cells, 20 000 cells/well were added in triplicate in an 
opaque 96-well microtitre plate and 50µl of 1X GSH-Glo™ reagent (prepared according to 
manufacturer’s guidelines) was added. GSH standards (0-25µM) were serially diluted (two-
fold) from a 5mM stock in de-ionised water. After 30min incubation at RT, 50µl of luciferin 
detection reagent was added to the wells (15min, RT). Luminescence was detected on a 
Modulus™ microplate luminometer. A standard curve was constructed and sample GSH 
concentrations (µM) were calculated.  
 
2.8 Lipid Peroxidation: 
 
2.8.1 Introduction- 
Lipid peroxidation can be defined as the oxidative deterioration of lipids containing any number 
of carbon- carbon double bonds. In response to membrane lipid peroxidation, cells may either 
promote cell survival or induce cell death. The overall process of lipid peroxidation consists of 
three steps: initiation, propagation and termination. Once lipid peroxidation is initiated, a 
propagation of chain reactions will take place until termination products are produced. Lipid 
peroxidation or reaction of oxygen with unsaturated lipid produces a wide variety of oxidation 
products including Malondialdehyde (MDA), which may be used as a reliable marker for 
oxidative stress (Mylonas, 1999). 
2.8.2 Protocol: 
Oxidative damage by ATO on A549 lung cells were assessed by the Thiobarbituric acid assay 
(TBARS). TBARS measures Malondialdehyde (MDA) which is the by-product of lipid 
peroxidation in cells. Following 48h treatment with ATO, cell culture supernatant (400µl) was 
dispensed, in duplicate, into glass tubes, with the addition of 2% phosphoric acid (200µl), 7% 
phosphoric acid (400µl) and TBA/BHT solution (400µl). A positive control of MDA and a 
negative control (400ul 3mM HCl) were prepared. All samples were adjusted to pH 1.5 and 
boiled for 15min to allow for the reaction depicted in Figure 2.6 to occur. Once cooled, butanol 
(1,5ml) was added to each test tube, vortexed and allowed to separate into distinct phases. The 
upper phase (800µl) was transferred into and centrifuged (840 x g, 6min, RT). 100µl from each 
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sample was aliquot into a 96-well microtitre plate in triplicate. The optical density was 
measured on a spectrophotometer at 532nm with reference wavelength of 600nm (Bio-Tek 
µQuant, USA). The assay was completed on three separate occasions to validate the obtained 
results. The sample means were calculated and divided by the absorption coefficient, 156mM-1 



















2.9 Caspase Activity: 
 
2.9.1 Introduction- 
Caspases are a family of cysteine proteases that play a crucial role in apoptosis as they are 
responsible for executing programmed cell death. Caspases 8 and 9 are initiator caspases and 
exist as inactive zymogens that are activated by dimerization. These initiator caspases activate 
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caspase 3/7 by cleavage of the procaspase. Once activated, one executioner caspase can cleave 
and activate other executioner caspases leading to an increased feedback loop of caspase 
activation (Brentnall, 2013). The luminometric caspase activity assay is used to determine the 
activity of caspases by the cleavage of caspase-specific luciferin substrate. The amount of light 















Figure 2.7 : Luminometric caspase activity assay depicting the reaction principle (Adapted 




Caspase-Glo® 3/ 7 (G8092), Caspase-Glo® 8 (G88201) and Caspase-Glo® 9 (CG8211) were 
used to assess apoptosis (Promega, Madison, USA). Reagents were prepared according to 
manufacturer’s guidelines. A549 cells were added to wells (three replicates) of a white 96-well 
microtitre plate (20,000 cells in 150 µl CCM/well). Caspase reagent (100µl) were added and 
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incubated in the dark (30min, RT). The luminescent signal was measured on a Modulus™ 
microplate luminometer. The assay was conducted on three separate occasions to confirm the 
data results. Caspase-3/-7, -8 and -9 activities were expressed as relative light units (RLU). 
2.10 Comet Assay: 
 
2.10.1 Introduction- 
Single cell gel electrophoresis (SCGE), otherwise known as the comet assay, is a procedure that 
is able to detect DNA strand breaks due to genotoxic stimuli. The fragmentation of DNA is a 
late apoptotic feature and is mediated by a group of proteins that are released downstream of the 
apoptotic cascade. The ‘comet’ refers to the appearance of the DNA from an individual cell 
following electrophoretic migration (Figure 2.8). The comet head contains high molecular 
weight DNA and the comet tail contains the leading ends of migrating fragments. The comet 
assay combines DNA gel electrophoresis with fluorescence microscopy to visualize migration 






Figure 2.8: Comet formation after electrophoresis (Olive, 2006). Negatively charged DNA 
contain breaks, DNA supercoils are relaxed and broken ends are able to migrate toward anode 
during electrophoresis (Figures B and C). If the DNA is undamaged the lack of free ends and 
the large size of the fragments prevent migration during electrophoresis (Figure A). Cancer cells 
however, will have some degree of DNA fragmentation due to mutations and alterations of 
genomic molecules. 
2.10.2 Protocol- 
The comet assay was used to determine DNA fragmentation in treated cells. Briefly, three 
frosted end microscope slides were prepared for both control and treatment, a first layer 
containing 400µl of 1% low melting point agarose (LMPA, 37°C) which were incubated at 4°C 
for 10 minutes, a second layer of 25µl of cell suspension (20,000 cells suspended in 0.1M PBS) 
from each sample with 175µl 0.5% LMPA (37°C), and 1µl GR Red (fluorescent staining dye) 
which was allowed to solidify for 10 minutes at 4°C. A third layer containing 200µl of 1% 
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LMPA (37°C) was then added and allowed to incubate for approximately 10minutes at 4°C. 
Cover slips were removed and slides were subjected to lysis (4°C, 1hr, protected from light) by 
being submerged in cell lysis buffer (2.5M NaCl, 100mM EDTA, 1% Triton X-100, 10mM Tris 
(pH 10) and 10% DMSO). The slides were equilibrated in electrophoresis buffer (300mM 
NaOH, 1mM Na2EDTA, pH 13; 20min) then electrophoresed (300mA, 25V, 35min) after which 
slides were washed three times (0.4M Tris, pH 7.4; 5min). Cover slips were placed onto slides 
and maintained overnight at 4°C. Slides were viewed using a fluorescent microscope (Olympus 
IXSI inverted microscope/510-560nm excitation and 590nm emission wavelengths). Images 
were captured and comet tails of 50 cells were measured using Life Science-Soft Imaging 
System (analySIS® v5). The assay was conducted on two separate occasions for confirmation 
of the first data set. The results were expressed as mean tail length in µm. 
2.11 Hoechst Stain Assay: 
 
2.11.1 Introduction- 
Hoechst is a water-soluble blue fluorescent, photosensitive dye, which is positive under 
physiological conditions. Hoechst 33342 is able to permeate viable cell membranes and stain 
double stranded nuclear DNA, thereby allowing the visualization and identification of 
replicating or apoptotic cells.  Hoechst 33342 binds to the minor groove of the double helix, 
preferentially to Adenosine-Thymine rich regions (Figure 2.9).  Hoechst excites at λ = 350nm 
and emits at λ = 461nm. Fluorescent microscopy is used to view the stained cells. The Hoechst 
stain is used to visualize the effect of a compound on DNA, apoptotic studies and for cell cycle 












2.11.2 Protocol-  
To assess the effect of ATO on nuclear material, cells were stained with Hoescht 33342. Cells 
seeded at a density of 500,000 cells/well in a 6 well plate were treated in 3 replicates for 48h. 
Cells were washed 3 times with 0.1M PBS and fixed with 10% paraformaldehyde for 5min. 
Cells were washed with 0.1M PBS before Hoescht working solution was added (10µg/ml, 
Molecular probes, Eugene, OR). Following 15min incubation at 37°C, cells were prepared for 
microscopy. Images were captured with an Olympus IXSI inverted microscope using 350nm 
excitation and 450nm emission filters. Three images per treatment replicate were captured at 
20x and 40x magnification.  
 
2.12 Western Blot: 
 
2.12.1 Protein Preparation- 
Cytobuster™ reagent (Novagen) supplemented with protease and phosphatase inhibitors 
(Roche, 05892791001 and 04906837001 respectively) was used for protein isolation. 
Cytobuster (200µl) was added to the cells (4°C, 10min) and centrifuged (180-x-g; 4°C, 10min) 
to obtain a crude protein extract.  
Following the isolation of protein from cells, crude extracts were quantified and standardised 
using the bicinchoninic acid (BCA) assay. The principle of the BCA assay is based on the 
Biuret reaction. The Biuret reaction measures the conversion of Cu2+ to Cu+. In alkaline 
conditions Cu2+ reacts with peptide bonds to form Cu+, which then reacts with BCA to produce 
an intense violet product at 37°C. BCA and copper interact with cysteine, tryptophan and 
tyrosine residues which lead to the colour development (Smith, 1985). It is necessary to 
quantify protein samples in order to know the concentration of protein within the sample. 
Protein standards (0; 0.2; 0.4; 0.6; 0.8, 1mg/ml) were made up using bovine serum albumin 
(BSA).The plate was then incubated for 1 hr at 37°C. Absorbance was read on the µQuant 
BioTek ELISA plate reader (λ = 562nm). The absorbance from the standards was used to 
construct a standard curve to calculate protein concentrations of the sample which were 
standardized to 0.8 mg/ml in Cytobuster.  Standardisation prior to electrophoresis is important 
because it is necessary to have the same volume and concentration of sample in each well in 
order to measure the behaviour of the sample throughout the assay.  
Following protein standardisation, samples are prepared with sample buffer containing SDS, 
tracker dye-bromophenol blue, glycerol and β-mercaptoethanol. Sodium dodecyl sulphate is an 
anionic detergent which is able to denature proteins by forming micelles around the 
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polypeptide. This gives the protein a negative charge and will be able to migrate in an electric 
field through the gel toward a positive electrode.  Bromophenol blue is used as a tracking dye to 
monitor the migration of the proteins during electrophoresis, β-mercaptoethanol breaks inter and 
intra-molecular disulfide bonds to accommodate proper separation of the bands according to 
size and glycerol adds density to the sample to allow for sinking of the sample to the bottom of 
the well, decreasing the chance of dissemination of samples between wells.  
Samples were then denatured by boiling for 15min  with a 4:1 dilution of 5 x Laemmli sample 
buffer [0.375 Tris-HCL pH 6.8;10% w/v SDS; 3% v/v glycerol; 2% w/v bromophenol blue; 
12% β-mercaptoethanol in dH2O] to activate SDS .  
 
2.12.2 Electrophoresis and Transfer- 
After samples were prepared, they were separated by size using Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE gels consist of a resolving gel, 
which is poured between two glass plates and topped by a short stacking gel. A lower 
percentage of acrylamide is used to improve transfer results. A 10% SDS-polyacrylamide 
resolving gel and a 4% stacking gel was prepared (dH2O, Tris, SDS, Bis/Acrylamide, 10% 
Ammonium phosphate sulphide, TEMED). TEMED is able to initiate Bis-acrylamide which 
acts as a cross linking agent, facilitating polymerization of the acrylamide gel. The cross-linked 
matrix formed by the polymerized acrylamide creates a porous structure through which the 
proteins will migrate. The migration allows for the separation proteins by molecular weight, 
with smaller proteins migrating further than larger proteins through the polyacrylamide matrix. . 
This makes it possible to clearly identify the target protein later through immunodetection with 
specific antibodies.	   Samples were loaded on the gel and electrophoresed at 150V for 1h.  
Thereafter, protein bands are transferred from the gel to a nitrocellulose membrane via a wet 
transfer method as explained by Mahmood and Yang (Mahmood, 2012). This is a sandwich of – 
gel, nitrocellulose membrane and fibre pads, placed in cassette and immersed in a buffer tank 
which is subjected to an electric field (Figure 2.10). Transfer to nitrocellulose membranes was 
conducted at 400mA for 1h.The application of a current allows for the transfer from the gel to 
the membrane. The wet transfer is considered more reliable because it is less likely to dry out 






















After blotting, the target protein was detected using appropriately matched and labelled 
antibodies. The typical immunodetection stage involves the following steps: 
Blocking:  The blot containing the transferred protein bands is incubated with a protein or 
detergent solution which covers the entire surface so that the antibodies do not bind non-
specifically to the membrane. The most common blocking solutions contain 3-5% BSA or non-
fat dried milk in a solution of Tris-buffered saline. Membranes were blocked with 5% non-fat 
dry milk (NFDM) in Tris buffer saline (20mM Tris-HCl (pH 7.4), 500mM NaCl and 0.01% 
Tween 20 (TBST) for 1h.  
Antibody incubation- following blocking: Following blocking, the membranes were probed 
with anti-p53 (AB26, Abcam), anti- bax (AB5714, Abcam), anti-c-PARP (ab11091), anti-
Smac/DIABLO, (AB110291, Abcam), anti-Bcl-2 (CS2827, Cell Signalling) and anti-Nrf2 
(CS8882, Cell Signalling) diluted to 1:1000 in 5% NFDM in TBST. The membranes were 
incubated for 1 hr on a shaker at RT and then overnight at 4°C. Since antibody preparations 
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varied, there was difference in the level of dilution required. As depicted in Figure 2.11, an 
indirect detection is whereby two different antibodies are used in sequence for the detection 
step.  
Detection with substrate- the label attached to the antibody, usually Horseradish Peroxidase 
(HRP) is detected using a substrate which produces a visible signal corresponding to the 
position of the target protein. Membranes were then washed 4 times (10ml TBST, 15min) and 
treated with horse radish peroxidase (HRP)-conjugated secondary antibody (goat anti-rabbit ; 












Figure 2.11: Summary of protein Immunodetection using the indirect method (primary and 
secondary antibody) (http://www.abdserotec.com/westernblotting). 
 
Membranes were washed 4 times (TBST, 15min) and immunoreactivity was detected by Clarity 
ECL substrate (Biorad). Enhanced chemiluminescence reagents are used for detection. Luminol 
was oxidized by HRP and an enhancer to produce light. The emitted light was detected by a 
CCD camera for light capture and was emitted as a band on an imaging system (Taylor, 2014, 
Mahmood, 2012). Images were captured with the Uvitech Image Documentation System 
(UViTech Alliance 2.7). Protein bands were analysed with the UViBand Advanced Image 
Analysis software (UViTech v12.4). Membranes were stripped with 5% hydrogen peroxide 
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(H2O2), rinsed thrice in TTBS, blocked in 5% NFDM (1 h; RT) and probed with HRP-
conjugated anti-β-actin (Sigma, St Louis, Missouri, USA). The results were expressed as mean 




2.13 Quantitative Polymerase Chain Reaction: 
 
2.13.1 Introduction- 
Polymerase chain reaction (PCR) is the technique used to exponentially amplify a target gene 
for further analysis. Quantitative reverse transcription PCR (RT-qPCR) is used when the 
starting material is RNA. In this method, RNA is first transcribed into complementary DNA 
(cDNA) by reverse transcriptase from total RNA or messenger RNA (mRNA). The cDNA is 
then used as the template for the qPCR reaction. The two step assay of RT-qPCR is used so that 
a stable pool of cDNA is made up and stored for multiple reactions. This allows for optimized 
reaction buffers and reaction conditions to be used.  
The principle of PCR is based on the amplification of a segment of DNA using specifically 
designed primer pairs, deoxynucleoside triphosphates (dNTPs), Taq polymerase, MgCl2 and a 
buffer solution. Taq DNA polymerase is used to direct the synthesis of DNA from 
deoxynucleotide substrates on a single-stranded DNA template. Taq polymerase adds 
nucleotides to the 3’ end of a specifically designed oligonucleotide when it is annealed to a 
longer template DNA, thus the enzyme can use a synthetic oligonucleotide as a primer and 
elongate its 3’ end to generate a region of double stranded DNA (Joshi, 2010, Lilit, 2013).  
 
There are three major steps in PCR, which are repeated for every 30 to 40 cycles. This is done 
in an automated cycler, which is able to heat and cool tubes with the reaction mixture in a very 
short time (Figure 2.12).  
1. Denaturation- this occurs at 94-96°C and allows for the breakage of weak hydrogen 
bonds that hold DNA stands together in a helix, allowing the strands to separate 
creating a single strand. 
2. Annealing- the mixture is cooled between 50-70°C. This allows for primers to bind to 
the complementary sequence in the template DNA. Ionic bonds are constantly formed 
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and broken between the single stranded primer and single stranded template. The stable 
bonds allow for the polymerase to attach and copy the template. 
3. Extension- The reaction is heated to 72°C, which is the optimal temperature for Taq 
polymerase. The enzyme extends the primers and adds nucleotides onto the primer in a 















Figure 2.12: Schematic of qPCR principle. With one cycle, a single segment of double stranded 
DNA template is amplified into two separate pieces of double stranded DNA. These two pieces 
are then available for amplification in the next cycle. As cycles are repeated, the template is 
increased exponentially (Adapted from (Nagiah, 2012)). 
 
2.13.2 Protocol- 
2.13.2.1 RNA isolation:  
RNA was first isolated from the control and ATO treated cells by adding 500µl Qiazol reagent 
(Qiagen) diluted in 500µl 0.1M PBS and incubated at -80°C for 1h. Chloroform (100µl) was 
then added and centrifuged (12,000xg, 15min, 4°C). The aqueous upper phase was then 
removed and added to a new eppendorf followed by the addition of propan-2-ol (250µl, 1h, -
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80°C) before centrifugation (12,000xg, 20min, 4°C). Samples were then washed in 75% cold 
ethanol and centrifuged (7,400xg, 15min, 4°C). Ethanol was then aspirated and RNA pellet was 
resuspended in 15µl nuclease-free water. Thereafter, RNA was quantified (Nanodrop 2000) and 
standardised to 1000ng/µl.  
2.13.2.2 cDNA Synthesis: 
A 20µl reaction volume containing 1µl RNA template, 4µl 5X iScript™ reaction mix, 1µl 
iScript reverse transcriptase and nuclease free water was used to synthesize cDNA (iScript™ 
cDNA Synthesis kit (BioRad; catalogue no 107-8890). Thermocycler conditions were 25°C for 
5min, 42°C for 30min, 85°C for 5min and a final hold at 4°C.  
2.13.2.3 Quantitative PCR: 
The mRNA expression of OGG1 (sense: 5’-GCATCGTACTCTAGCCTCCAC-3’, anti-sense: 
5’-AGGACTTTGCTCCCTCCAC-3’) was investigated using Q-PCR. Primer sequences were 
obtained from Inqaba Biotechnologies. Amplification proceeded in triplicate, in a 25µl reaction 
consisting of: 12.5µl 5X iScript reaction mix, 2µl of cDNA, 1µl of the primer set and 8.5µl of 
RNase-free water. Cycling conditions were: initial denaturation (95°C, 4min), 37 cycles of 
denaturation (95°C, 15s), annealing (57°C, 40s) and extension (72°C, 30s) followed by a plate 
read for 37 cycles (CFX96 Touch™ Real Time PCR Detection System (Bio-Rad)). The 
housekeeping gene, Glyceraldehyde-3phosphate dehydrogenase (GAPDH) was run under the 
same conditions. The analysis of results made use of the method described by Livak and 
Schmittgen (2001) was used. . Results are expressed as fold change (2-∆∆Ct) relative to the 
housekeeping gene, GAPDH (sense: 5’-TCCACCACCCTGTTGCTGTA-‘3 and anti-sense: 5’-
ACCACAGTCCATGCCATCAC-‘3) and control (Livak, 2001). 
 
 
2.14 Statistical Analysis: 
Statistical analyses were performed using GraphPad Prism version 5.00 software package 
(GraphPad PRISM®) and Microsoft excel 2010. Data are expressed as mean ± standard error of 
the mean (SEM). Comparisons were made using the unpaired Student t-tests using Welch 







3.1 Cell Viability: 
 
3.1.1 MTT assay: 
The toxicity of ATO to A549 cells was determined using the MTT assay. A dose-response was 
determined using ATO concentrations in the range 0 to 150µg/ml for 48h (95% Cl=31.34 to 
44.68) (Figure 3.1). Analysis of the dose dependent curve showed that 39.25µg/ml ATO was 
sufficient to cause 50% of A549 cytotoxicity. This IC50 concentration was used in all 










Figure 3.1: Cell viability of A549 cells treated with ATO for 48 hours. Data is represented as a 
percentage of viable cells relative to the untreated control (0 µM). A dose-dependent decline in 
A549 cell viability after ATO treatment. 
 
3.1.2 ATP Assay: 
Cellular ATP levels were measured using the Cell Titre-Glo® assay. ATO significantly reduced 
ATP levels with a 3.07-fold decrease (38460 ± 2621 RLU) compared to the control (98050 ± 













Figure 3.2: ATP levels in ATO treated A549 cells versus Control (*** p≤ 0.001: p=0.0040). 
RLU: relative light units. 
 
3.1.3 LDH Assay: 
Extracellular levels of LDH were quantified using a colorimetric assay. Results showed a 1.94-
fold increase in LDH levels in the supernatant of the ATO treated cells (2.749 ± 0.06714) 
compared to that of the control supernatant (1.417 ± 0.002496). Results are presented as mean 














3.2 Oxidative Stress: 
	  
3.2.1 Lipid Peroxidation: 
Lipid peroxidation, caused by ROS was assessed by quantifying MDA levels (Figure 3.4). The 
MDA levels were markedly raised in the ATO treated cells (17.62 ± 0.6086) compared to the 










Figure 3.4: Extracellular MDA levels in Control and ATO treatment (** p≤ 0.01: p=0.0051). 
 
 
3.2.2 Glutathione Assay: 
Glutathione (GSH) concentrations were measured using the GSH-Glo™ Glutathione assay as a 
marker for intracellular anti-oxidant capacity (Figure 3.5). The levels of endogenous 
antioxidant, GSH, significantly decreased in the ATO treatment compared to the control 

















Figure 3.5: Anti-oxidant, GSH, expression in Control and treated cells (*** p≤ 0.001: p=0010). 
 
3.2.3 Nrf2 protein Expression: 
Regulator of Antioxidant proteins, Nrf2, expression was measured using Western Blot. Results 
showed significantly lowered expression (1.29- fold) in the treatment compared to the control 
(0.1954 ± 0.004683 vs control: 0.2516 ± 0.008478 RBD: p=0.0102). The results of the Nrf2 













Figure 3.6: Nrf2 expression image and band density graph of control and ATO-treated Protein 
(* p≤ 0.01: p= 0.0102). 
3.3 Apoptosis: 
 
3.3.1 Caspase Activity: 
Intracellular activity of caspases -9, -8 and -3/7 were measured. Table 1 represents the apoptotic 
induction of ATO in A549 cells. There was a significant increase in caspase -9 (1.99-fold), 
caspase-8 (1.98- fold) and caspase -3/7 (1.66 -fold) activities in the ATO-treated cells compared 
to the untreated, control cells. Bar graphs shown in Appendix 2 (A-C). 
 
RLU: Relative Light units; sem: Standard error of the mean  
3.3.2 Comet Assay: 
The comet assay was performed to evaluate DNA fragmentation after ATO exposure. Longer 
comet tail length is associated with higher DNA fragmentation. Figure 3.7  shows comet tails 
were significantly longer in the cells treated with ATO compared to the control cells (Figure 
3.8), indicating that ATO is genotoxic to A549 cells (19.45 ± 0.5768 vs 19.45 ± 0.5768: p < 








Mean RLU ± sem 
ATO                      
Mean RLU ± sem 
p-value 
Caspase 9 1832000 ± 1109 2237000 ± 48910  
0.0143  
(* p≤ 0.01) 
Caspase 8 777100 ± 16390  1542000 ± 23940  
0.0001  
(***p≤ 0.001) 
Caspase 3/7 19260 ± 1436  40830 ± 164.7  
0.0426 
(*p≤ 0.01) 














Figure 3.8: Comet tail length was significantly higher in ATO treated cells compared to control 
(*** p≤ 0.001: p<0.0001). 
3.3.3 Hoechst Assay: 
Using the Hoechst stain 33342, the detection of morphological hallmarks of apoptosis were seen 
including nuclear condensation, cell shrinkage and apoptotic bodies (Figure 3.9 [B]). This was 
compared to the control cells which showed normal cell division at different stages of the cell 
cycle (Figure 3.9 [A]). Cell density was at a lesser extent in the ATO-treated cells compared to 








Figure 3.9: Hoechst stained cells show normal cell cycle morphology in A549 control cells (A) 




3.3.4 DNA repair enzymes- PARP and OGG1: 
The mRNA expression of OGG1 was assessed by qPCR (Figure 3.10). OGG1 gene expression 
was significantly diminished (p=0.0363) in the ATO- treatment relative to the normalized 
control (2.655 ± 0.2089 vs normalized control 1.010 ± 0.005773). The Ct values from the 
OGG1 qPCR were used to calculate fold change (±: standard deviations from the mean).Fold 












Figure 3.10: OGG1 mRNA expression was 2.28 fold lower in ATO-induced RNA compared to 











Results for western blot analysis of cleaved PARP yielded an 89kDa and 24kDA fragment 
(Figure 3.11). Analysis of the fragments showed a 2.39-fold decrease in band intensity of the 
89kDA fragment (0.2606 ± 0.0004324 vs control: 0.7329 ± 0.02424 RBD: p=0.0026) and a 1.14 
fold increase in expression of the 24kDA fragment (0.5837 ±0.02087 vs control: 0.4705 ± 














Figure 3.11: Western Blot images and graph of cleaved PARP. Protein expression analysis 
showed a significant decrease in the 89 kDA fragment (**p≤ 0.001: p=0.0026) and an increase 





89 kDA PARP 




3.3.5 Apoptotic Markers: 
Western blotting was employed to assess the effects of ATO on the protein expression of 
apoptotic markers Bax, p53, Smac/DIABLO and Bcl-2 (Figure 3.12). ATO induced significant 
increases in expression of proapoptotic protein Bax (0.3079 ± 0.001639 vs control: 0.1442 ± 
0.008411 RBD: fold change- 2.26); tumour suppressor protein p53 (0.5112 ± 0.001380 vs 
control: 0.3358 ± 0.01474 RBD: fold change- 1.78) and Smac/DIABLO (0.6823 ± 0.02125 
RBD vs 0.4615 ± 0.004293 RBD: fold change- 1.35). Anti-apoptotic protein Bcl-2 expressed a 
1.21-fold decrease (0.2529 ± 0.001878 vs control: 0.2905 ± 0.01937 RBD: p=0.3039) (±: 

















Figure 3.12: Western blot images and band intensity graphs for the expression of (A) Bax (*p≤ 
0.01: p=0.0333) (B) p53 (**p≤ 0.001: p=0.0070) (C) Smac/DIABLO (**p≤ 0.001: p=0.0095) 






Cancer and heart disease are the major non-communicable causes of death worldwide. Non-
small cell lung cancer accounts for approximately 80-85% of all cases of cancer-related 
mortality in both men and women globally. The major reasons of such high mortality is that 
NSCLC becomes resistant to chemotherapeutic treatments and radiation therapy. Furthermore, 
NSCLC is generally diagnosed at very late stages and surgical intervention is not permissible 
(Siegel, 2012, Molina, 2008). 
Systemic anti-cancer therapies, such as chemotherapy, can produce acute and chronic organ 
damage. In addition, the cost of chemotherapy can be very expensive, thus, it is necessary for 
improved or novel strategies for lung cancer treatment and prevention by providing therapy with 
minimal side effects to the patient (Cassileth, 1996).  
Statins are inhibitors of HMGCR which prevent cardiovascular disease and lower LDL 
cholesterol. In recent years, the anti-tumour activity of statins, independent of cholesterol 
reduction, have been established. These anti-tumour properties have been seen in prostate (Lee, 
2006), colon (Agarwal, 1999), leukemic (Xia, 2001), pancreatic (Kusama, 2001) and breast 
cancer cells (Denoyelle, 2001).  The positive effects of statins outweigh the minor, 
asymptomatic adverse effects and are available at an inexpensive cost. Preclinical studies have 
demonstrated that lipophilic statins (more accessible to tumour cells) such as lovastatin and 
atorvastatin have better anti-tumour activity, relative to hydrophobic statins such as pravastatin 
(Cafforio, 2005).   
Apoptosis is a succession of precisely regulated events which is altered by cancer cells, leading 
to cell survival and tumour growth (Fulda, 2009). Therefore, triggering apoptosis can be a 
promising strategy for cancer chemoprevention. 
Our hypothesis on the anti-proliferative properties of ATO on A549 lung cells was formulated 
on the basis of studies evidencing the pro-apoptotic effects of statins both in vivo and in vitro 
(Wong, 2011, Xia, 2001, Agarwal, 1999, Kusama, 2001, Denoyelle, 2001).   
Mitochondria are dynamic organelles that constantly undergo adaptations suited to the 
conditions of the cell; they play a major role in cellular metabolism and are a key source of ROS 
generation in cells (Hwang, 2013). The inhibition of HMGCR by statins has been linked to 
mitochondrial dysfunction triggered by increased ROS and decreased prenylated protein 
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(Tricarico, 2015). In the present study, ATO increased MDA levels (Figure 3.4), a marker of 
lipid peroxidation induced by increased ROS production. 
Under normal physiological conditions ROS regulate intracellular signalling, however, under 
conditions of excessive ROS production, the endogenous antioxidant system may have been 
depleted leading to accumulated ROS and increased oxidative damage (Valko, 2006). This 
imbalance in oxidative stress leads to decreased expression of Nrf2.  A direct consequence 
results in inadequate replenishment of the antioxidant GSH (Shih, 2005). The increase in lipid 
peroxidation by ATO correlated with decreased Nrf2 protein expression (Figure 3.6) and the 
significantly decreased GSH levels (Figure 3.5) in the A549 cells. 
Cellular targets of ROS include DNA, proteins and phospholipids on cell membranes. ATO 
increased LDH activity in the culture supernatants (Figure 3.3), a strong indicator of A549 cell 
membrane damage.  The lipophilic nature of ATO is responsible for cell membrane damage. 
The metabolic function of the A549 cells, after inhibition of HMGCR, was compromised as 
measured by the dose dependent decrease in MTT conversion (Figure 3.1) and decreased 
intracellular ATP production (Figure 3.2). The inhibition of HMGCR leads to the accumulation 
of acetyl-coA in the mt which is converted to citrate and shuttled to the cytosol. This results in 
decreased reducing equivalents required for ATP production (Diechmann, 2010).  
Oxidative stress may be genotoxic to DNA by the modification of purine and pyrimidine bases 
leading to strand breaks. ROS reacts with DNA bases to form cytotoxic oxidative base lesions, 
including 7, 8-dihydro-8-oxoguanine (8-oxoG). This oxidised base lesion is different from 
guanine as it pairs incorrectly with adenine, eventually leading to transversion mutations (Youn, 
2007). ATO exposure resulted in DNA damage as evidenced by increased strand breaks and 
comet tail lengths (Figure 3.7). OGG1, a mitochondrial base excision repair enzyme, removes 8-
oxoguanine base lesions in both nuclear and mitochondrial genomes, thereby suppressing cell 
death (Liu, 2011, Ruchko, 2011).  
In response to DNA damage, PARP-1 catalyses the poly-ADP-ribosylation of specific nuclear 
proteins in order to repair DNA strand breaks and overall genomic maintenance (Boulares, 
2013, DÁmours, 2001). PARP-1 was cleaved by caspase-3/7 during apoptosis into an 89kDa 
and 24kDa fragment (Figure 3. 11), thus rendering it inactive.  
The genotoxic role of ATO may be attributed to the increase in DNA strand breaks, decreased 




ATO exposure resulted in the initiation of the extrinsic apoptotic pathway as evidenced by 
increased caspase 8, 3 and 7 (Table 1). The extrinsic apoptotic pathway makes use of 
transmembrane death receptor- mediated reactions which involve the TNF –α family of death 
receptors. These death receptors contain death domains and upon ligand binding, recruit adapter 
FADD via the death domain. Adapter proteins bind to death effector domain-containing 
caspases-8 giving rise to the formation death inducing signalling complex (DISC), allowing for 
the activation of caspase 8 which can directly cleave and activate effector caspases 3 and 7 
(Johnstone, 2002, Fulda, 2006).  
It is interesting to note that caspase 9 was also elevated during our investigation, indicating that 
the intrinsic apoptotic pathway was simultaneously induced by ATO.  During ATO-mediated 
induction of the intrinsic apoptotic pathway, p53 protein expression was significantly increased 
(Figure 3.12 B) allowing for the transcription and translocation of Bax to the outer 
mitochondrial membrane while inhibiting anti-apoptotic protein Bcl-2 (Figure 3.12 D). This was 
validated by the significant 2.2 fold increase in Bax protein expression after acute ATO 
exposure (48 h). A conformational change then occurs and there is depolarization due to a loss 
in matrix metalloproteinase (MMP). Upon disruption, proteins that were situated within the 
outer and inner mitochondrial membrane are released into the cytosol including Cytochrome C 
and Smac/DIABLO (Fulda, 2006, Chai, 2014).  
Cytochrome c, together with Apaf1 and pro-caspase 9 form an apoptosome, leading to the 
cleavage and activation of caspase 9 and executioner caspases which then initiate the 
morphological hallmarks of apoptosis including a condensed chromatin and apoptotic bodies. 
This was seen in the Hoechst assay (Figure 3.9) which showed fewer cells and characteristic 
apoptotic morphology after the ATO treatment.  
A class of molecules involved in the regulation of apoptosis is IAP proteins (Fulda, 2006). 
Inhibitor of apoptosis proteins prevent cell death by suppressing the activity of caspases. 
Proteins such as Smac/DIABLO activate caspases by facilitating the neutralisation of inhibitors 
of apoptosis proteins (IAPs). In the cytosol, Smac/DIABLO binds to one molecule of IAP in a 
BIR-dependent manner to allow for the displacement of caspase 9 from XIAP (Fulda, 2006). 
ATO increased Smac/DIABLO protein expression (Figure 13.12 C) which correlated with the 























Figure 4: Schematic overview of the apoptosis inducing properties of ATO on human lung 














Current cancer therapies are associated with numerous adverse effects which accentuates the 
need to develop safer therapies. There is growing evidence from preclinical and clinical 
investigations that statins may be beneficial in the treatment of malignancies. 
In this dissertation, the apoptotic effect of ATO on A549 human non-small lung cancer 
(NSCLC) cells were demonstrated (Figure 4). ATO was found to exhibit strong growth 
inhibitory effects on NSCLC cells. 
The pro-apoptotic effect of ATO was associated with low ATP availability in A549 cells. This 
was due to the inhibition of HMGCR, which lead to mitochondrial dysfunction and increased 
lipid peroxidation. In this study it was shown, mechanistically, that ATO activates the intrinsic 
and extrinsic apoptotic pathway via caspase 9 and 8 respectively. 
Taken together, ATO inhibited lung adenocarcinoma cell survival and promoted apoptosis. 
Given the importance of the suppression of apoptosis in contributing to tumour growth ad 
invasion, the drug may have potential in the treatment of lung cancer. Based on the present 
findings, it would be worthwhile to further investigate the effects of ATO on cell cycle arrest 
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ATO Concentration (µg/ml) Average Absorbance % Viability Log [ATO] 
0	   1,426	   100,00	    
1	   1,354	   94,95	   0,000	  
2	   1,459	   102,31	   0,301	  
5	   1,466	   102,78	   0,699	  
10	   1,603	   112,41	   1	  
15	   1,102	   77,28	   1,176	  
20	   1,053	   73,87	   1,301	  
25	   0,851	   59,70	   1,398	  
50	   0,703	   49,32	   1,699	  
75	   0,355	   24,87	   1,875	  
100	   0,180	   12,62	   2,000	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Figure 1: Caspase-3/-7 activity was significantly higher in cells exposed to ATO compared to 












Figure 2: The activity of caspase-8 was significantly increased in cells exposed to ATO 
































y = 0.8457x + 0.0948 
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APPENDIX 8.4 
















Figure 1: Calibration curve using known concentrations of bovine serum albumin for the 





0 0,2 0,4 0,6 0,8 1 
OD1 0,101	   0,229	   0,422	   0,64	   0,823	   0,963	  
OD2 0,105	   0,248	   0,429	   0,603	   0,764	   0,892	  
OD3 0,1	   0,302	   0,44	   0,533	   0,757	   0,967	  
       






Table 2: Standardisation of protein using the calibration curve for sodium dodecyl sulphide 


























C2 (mg/ml) V2 (µl) V1(µl) 
Control 1,521 1,686	   0.800 200 94,899 





The 2-ΔΔCT Method for Analysis of quantitative PCR 
 
The 2-ΔΔCt method refers to the method of analysis used to obtain a relative fold change of a 
treated sample compared to an appropriate control group as described by Livak and Schmittgen 
(2001). 
Equations: 
∆C (t) = Gene (Ct) – Housekeeping gene (Ct)  
∆∆C (t) = Experimental group (∆Ct) – Control (∆Ct) 
Fold change = 2- ΔΔC(t) 
Control Control Control ATO ATO ATO 
OGG1 
 
27,73 28,00 27,82 28,47 28.27 29,09 
GAPDH 
 
9,89 9,80 9,55 9,08 9,55 9,47 
ΔC(t) 
 
17,83 18,20 18,27 19,39 18,73 19,62 
Average Control 
18,10    
ΔΔC(t) 
 
0,27	   0,10 0,17 1,29 0,62 1,52 
Fold change 
 
1,204017	   0,933841	   0,889394	   0,408726	   0,649107	   0,349117	  
 
 
